In ZINC since | Heavy atoms | Benign functionality |
---|---|---|
November 21st, 2005 | 15 | No |
Popular Name: Amiloride hydrochloride Amiloride hydrochloride
Find On: PubMed — Wikipedia — Google
CAS Numbers: 137053-86-2 , 17440-83-4 , 17440-83-4, 2016-88-8 , 17440-83-4, 2016-88-8 [anhydrous], 2609-46-3 [amiloride] , 2016-88-8 , 2609-46-3 , [17440-83-4] , [2016-88-8] , [2609-46-3]
17440-83-4; Amiloride hydrochloride (USP); D00649; Midamor (TN)
17440-83-4; Amiloride hydrochloride dihydrate; Prestwick_15
2016-88-8 (anhydrous hydrochloride)
2609-46-3; Amiclaran (TN); Amiloride (INN); D07447
3,5-diamino-6-chloro-N-(diaminomethylidene)pyrazine-2-carboxamide
3,5-Diamino-N-(aminoiminomethyl)-6-chloropyrazinecarboxamide
3,5-Diamino-N-(aminomethyl)-6-chloropyrazine carboxamide hydrochloride dihydrate
3,5-diamino-N-carbamimidoyl-6-chloropyrazine-2-carboxamide
3,5-diamino-N-carbamimidoyl-6-chloropyrazine-2-carboxamide dihydrate hydrochloride
3,5-diamino-N-[amino(imino)methyl]-6-chloropyrazine-2-carboxamide
Amikal (Hydrochloride dihydrate)
Amilorid hydrochlorid-2-wasser
Amilorida [INN-Spanish];Amiloride hydrochloride hydrate;Amiloridum [INN-Latin];Amyloride
amilorida; amiloride; amiloridum
AMILORIDE (SEE ALSO: AMILORIDE HCL (2016-88-8))
Amiloride hydrochloride (Midamor)
Amiloride hydrochloride dihydrate
Amiloride hydrochloride hydrate
Amiloridehydrochloridedihydrate
Amiloridum [INN-Latin]; Amiloride hydrochloride hydrate; Amilorida [INN-Spanish]; Amyloride
Amiloridum [INN-Latin];Amiloride hydrochloride hydrate;Amilorida [INN-Spanish];Amyloride
Amipramidin; Amipramizid; Amipramizide; CPD-10324; Guanamprazin; Guanamprazine; Midamor; amiloride
CPD000449325; Pyrazinecarboxamide, 3,5-diamino-N-(aminoiminomethyl)-6-chloro- [CAS]
CPD000449325; Pyrazinecarboxamide, 3,5-diamino-N-(aminoiminomethyl)-6-chloro- [CAS]; SAM001246996
INN); Amiloride Hydrochloride (FDA
Midamor (Hydrochloride dihydrate)
Midamor, Colectril, Amipramizide, Guanamprazine hydrochloride
MK-870 (Hydrochloride dihydrate)
N-(3,5-Diamino-6-chloro-pyrazine-2-carbonyl)-guanidine
N-Amidino-3,5-diamino-6-chloropyrazinecarboxamide
N-Amidino-3,5-diamino-6-chloropyrazinecarboxamide hydrochloride
N-Amidino-3,5-diamino-6-chlorpyrazincarboxamid
N-Amido-3,5-diamino-6-chloropyrazine carboxamide
N-Amido-3,5-diamino-6-chloropyrazine carboxamide hydrochloride dihydrate
Pyrazinecarboxamide, 3,5-diamino-N-(aminoiminomethyl)-6-chloro-
Pyrazinecarboxamide, 3,5-diamino-N-(aminoiminomethyl)-6-chloro-, monohydrochloride
Type pH range | xlogP | Des A‑Pol Apolar desolvation (kcal/mol) | Des Pol Polar desolvation (kcal/mol) | H Don H-bond donors | H Acc H-bond acceptors | Chg Net charge | tPSA (Ų) | MWT Molecular weight (g/mol) | RB Rotatable bonds | DL |
---|---|---|---|---|---|---|---|---|---|---|
Ref Reference (pH 7) | -1.37 | -3.38 | -10.68 | 8 | 8 | 0 | 159 | 229.631 | 1 | ↓ |
Hi High (pH 8-9.5) | -1.37 | -3.35 | -39.89 | 7 | 8 | -1 | 157 | 228.623 | 1 | ↓ |
Note Type | Comments | Provided By |
---|---|---|
mechanism | . | ZereneX Building Blocks |
ALOGPS_SOLUBILITY | 1.22e+00 g/l | DrugBank-approved |
purity | 9.500000000000000e+001 | Enamine Building Blocks Enamine Building Blocks |
MP | >240° | Oakwood Chemical |
UniProt Database Links | ADA2A_PIG; AOC1_HUMAN; AOC1_MOUSE; AOC1_PIG; AOC1_RAT; AOCX_BOVIN; AOCY_BOVIN; DEG1_CAEEL; DEGZ_CAEEL; DEL1_CAEEL; FANA_HELAS; GLIC_GLOVI; LODA_MARM1; MEC10_CAEBR; MEC10_CAEEL; MEC4_CAEBR; MEC4_CAEEL; MEC6_CAEEL; NACH_DROAN; NACH_DROME; NACH_DROVI; NHAA_V | ChEBI |
mechanism | Amiloride exerts its potassium sparing effect through the inhibition of sodium reabsorption at the distal convoluted tubule, cortical collecting tubule and collecting duct | IBScreen Bioactives |
mechanism | Amiloride is not an aldosterone antagonist and its effects are seen even in the absence of aldosterone. | IBScreen Bioactives |
Indications | cystic fibrosis | KeyOrganics Bioactives |
Patent Database Links | EP0795327; EP1106210; EP1634607; EP1695716; EP1717226; EP1731140; EP1767534; EP1839648; EP1844774; EP1862181; EP1908834; EP1941883; EP1967192; GB2264710; US2002115655; US2004147575; US2005009870; US2005014786; US2005043325; US2005080087; US2005187267; US2 | ChEBI |
Patent Database Links | EP1553091; US2005059655; US2006189603; US2007037821; US2007238740; US2008275093; US2008287407; US2008293678; US2008293702; WO2005018561; WO2005023183; WO2005030135; WO2005060603; WO2006055542; WO2006078995; WO2006091716; WO2006093864; WO2006099058; WO2006 | ChEBI |
Therapy | Epithelial Na+ channel blocker | SMDC Iconix |
mechanism | Inhibitor of sodium reabsorption in the distal convoluted tubules and collecting ducts in the kidneys by binding to the amiloride-sensitive sodium channels. | IBScreen Bioactives |
therap | Na+ channel inhibitor, diuretic | MicroSource Spectrum |
PUBCHEM_SUBSTANCE_COMMENT | NCC_SAMPLE_SUPPLIER : Tocris Cookson Ltd.; NCC_SUPPLIER_STRUCTURE_ID : 101735; 2 water; 1 hydrogen chloride | NIH Clinical Collection via PubChem |
Target | Others | Selleck Chemicals |
biological_use | Potassium-sparing diuretic | IBScreen Bioactives |
PUBCHEM_SUBSTANCE_COMMENT | SAMPLE_SUPPLIER: Tocris Bioscience; SUPPLIER_STRUCTURE_ID: 101735; SALT: 2 water; 1 hydrogen chloride | NIH Clinical Collection via PubChem |
Target | Sodium Channel,Calcium Channel | Selleck Chemicals |
mechanism | this decreases the net negative potential of the tubular lumen and reduces both potassium and hydrogen secretion and their subsequent excretion. | IBScreen Bioactives |
mechanism | This promotes the loss of sodium and water from the body, but without depleting potassium. | IBScreen Bioactives |
Code | Description | Organism Class | Affinity (nM) | LE (kcal/mol/atom) | Type |
---|---|---|---|---|---|
AA2AR-1-E | Adenosine A2a Receptor (cluster #1 Of 4), Eukaryotic | Eukaryotes | 3280 | 0.51 | Binding ≤ 10μM |
ACCN3-1-E | Amiloride-sensitive Cation Channel 3 (cluster #1 Of 2), Eukaryotic | Eukaryotes | 4400 | 0.50 | Binding ≤ 10μM |
AOC3-2-E | Amine Oxidase, Copper Containing (cluster #2 Of 2), Eukaryotic | Eukaryotes | 10000 | 0.47 | Binding ≤ 10μM |
SCNNA-1-E | Amiloride-sensitive Sodium Channel Alpha-subunit (cluster #1 Of 1), Eukaryotic | Eukaryotes | 776 | 0.57 | Binding ≤ 10μM |
UROK-4-E | Urokinase-type Plasminogen Activator (cluster #4 Of 4), Eukaryotic | Eukaryotes | 7000 | 0.48 | Binding ≤ 10μM |
Z50425-3-O | Plasmodium Falciparum (cluster #3 Of 22), Other | Other | 7943 | 0.48 | Functional ≤ 10μM |
Uniprot | Swissprot | Description | Affinity (nM) | LE (kcal/mol/atom) | Type |
---|---|---|---|---|---|
SCNNA_HUMAN | P37088 | Amiloride-sensitive Sodium Channel Alpha-subunit, Human | 776 | 0.57 | Binding ≤ 1μM |
AA2AR_HUMAN | P29274 | Adenosine A2a Receptor, Human | 3280 | 0.51 | Binding ≤ 10μM |
ACCN3_HUMAN | Q9UHC3 | Amiloride-sensitive Cation Channel 3, Human | 4400 | 0.50 | Binding ≤ 10μM |
SCNNA_HUMAN | P37088 | Amiloride-sensitive Sodium Channel Alpha-subunit, Human | 776 | 0.57 | Binding ≤ 10μM |
AOC3_RAT | O08590 | Amine Oxidase, Copper Containing, Rat | 10000 | 0.47 | Binding ≤ 10μM |
UROK_HUMAN | P00749 | Urokinase-type Plasminogen Activator, Human | 2511.88643 | 0.52 | Binding ≤ 10μM |
Z50425 | Z50425 | Plasmodium Falciparum | 7943.28235 | 0.48 | Functional ≤ 10μM |
Description | Species |
---|---|
Stimuli-sensing channels |
Description | Species |
---|---|
Adenosine P1 receptors | |
Dissolution of Fibrin Clot | |
G alpha (s) signalling events | |
NGF-independant TRKA activation | |
Stimuli-sensing channels |